| Description | Lefradafiban（BIBU-104） is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes. |
| In vivo | Lefradafiban（口服30、45、和60毫克；每日三次，持续48小时；用于接受血管成形术的稳定性心绞痛患者）是一种有效的口服糖蛋白IIb/IIIa受体阻断剂。[1] |
| Synonyms | BIBU 104, BIBU104, BIBU-104 |
| molecular weight | 439.46 |
| Molecular formula | C23H25N3O6 |
| CAS | 149503-79-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (102.4 mM) |
| References | 1. Akkerhuis KM, et al. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50. 2. Akkerhuis KM, et al. Fibrinogen Receptor Occupancy Study (FROST) Investigators. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J. 2000 Dec;21(24):2042-55. 3. Müller TH, et al. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997 Aug 19;96(4):1130-8. 4. Drewe J, et al. Absorption of lefradafiban from different sites of the gastrointestinal tract. Br J Clin Pharmacol. 2000 Jul;50(1):69-72. |